SC-U02

N/A

Report date: 2024/04/07 11:35:08

Base Information

Drug NameSC-U02

Drug Alias NameSC-U02nvGT UCART19

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Large B-Cell, Diffuse

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesSunnycell Therapeutics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesThe Second Affiliated Hospital of the Air Force Medical University of the Chinese People's Liberation Army

Inactive CompaniesN/A

Active IndicationsLymphoma, Large B-Cell, Diffuse

Inactive IndicationsN/A

Other Information

ATC CodeN/A